- Home
- XBIO
as 11-15-2024 4:00pm EST
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | FRAMINGHAM |
| Market Cap: | 5.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 30.0K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.78 - $5.20 | Next Earning Date: | 11-12-2024 |
| Revenue: | $2,523,427 | Revenue Growth: | 7.15% |
| Revenue Growth (this year): | -11.65% | Revenue Growth (next year): | -18.18% |
Latest Xenetic Biosciences Inc. News
XBIO Breaking Stock News: Dive into XBIO Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Xenetic Biosciences Third Quarter 2024 Earnings: Misses Expectations
ACCESSWIRE
5 days ago
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Associated Press Finance
5 days ago
Xenetic Biosciences: Q3 Earnings Snapshot
ACCESSWIRE
6 days ago
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
ACCESSWIRE
11 days ago
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
ACCESSWIRE
a month ago
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
ACCESSWIRE
a month ago
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
ACCESSWIRE
2 months ago
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
Compare XBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XBIO Xenetic Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.